Basel Medical Group Business Summary

Basel Medical Group Ltd (BMGL) is a Singapore-based healthcare provider that generates revenue primarily through specialized clinical services, including orthopedic surgery, trauma care, sports medicine, and neurosurgery. The company operates an asset-light business model, leveraging long-standing partnerships with corporate clients in labor-intensive sectors like construction, marine, and oil & gas to drive recurring demand for occupational and musculoskeletal care. Following its January 2026 acquisition of Bethesda Medical for $6.5 million, BMGL has expanded its revenue streams to include diagnostic imaging, health screening, and general outpatient services, positioning itself as an integrated healthcare ecosystem. In the competitive landscape, BMGL contends with small-cap peers such as EUDA Health, P3 Health Partners, Marpai, and Mobilehealth Network Solutions, distinguishing itself through its niche focus on high-acuity surgical specialties and its established footprint in Singapore’s private medical sector. The group was founded by Dr. Kevin Yip Man Hing, a prominent orthopedic surgeon who established the company’s first clinic in 2001 before its 2023 incorporation and subsequent 2025 NASDAQ IPO. The current leadership team is led by Interim CEO and Group Chief Health Officer Dr. Yen Feng (Darren) Chhoa, who brings extensive pedigree from senior roles at Fullerton Health Group and HMI Group, and Executive Chairman Keng Leong (Raymond) Fung. Other key executives include Group CFO Jianing Lu and Chief Commercial Officer Tan Boon Chye (Darren), who was appointed in August 2025 to spearhead regional expansion. BMGL is a controlled company of Rainforest Capital VCC (under the Basel Medical Fund), which maintains a majority stake, with a board of directors that includes independent members Paul Freudenthaler, Tony Chen, and Kwek Yoon Soong.